Streetbeat News

Analyst Ratings

ESTA

Mizuho analyst Anthony Petrone maintains a 'Buy' rating on Establishment Labs Hldgs (NASDAQ:ESTA) but has lowered the price target from $80 to $50.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 8:20 pm

BLMN

EAT

PLAY

BMO Capital Markets analyst Andrew Strelzik reiterated the Market Perform rating on Bloomin' Brands, Inc. (NASDAQ:BLMN), lowering the price target to $24 from $25. The company reported Q3 FY23 sales growth of 2.3% YoY to $1.079 billion, missing the analyst consensus estimate of $1.085 billion. The analyst remains on the sidelines on BLMN shares due to concerns about the macro environment and potential for a softer spending environment. The analyst also mentioned Brinker International, Inc. (NYSE:EAT) and Dave & Buster's Entertainment, Inc. (NASDAQ:PLAY) as preferred near-term opportunities in Restaurants.

Portfolio Pulse from Nabaparna Bhattacharya

November 08, 2023 | 8:18 pm

AMC

AMC Entertainment Holdings, Inc (NYSE:AMC) is expected to report a loss of 38 cents per share on revenues of $1.17 billion for Q3. The company's stock fell over 2% ahead of the earnings announcement. Wedbush maintained a Neutral rating on AMC and lowered the price target from $19 to $11. The firm is optimistic that AMC could post positive guidance for Q4 due to the success of Taylor Swift’s 'Eras Tour Concert' Movie and Beyonce’s upcoming movie release. From a technical analysis perspective, AMC’s stock looks bullish heading into the event.

Portfolio Pulse from Melanie Schaffer

November 08, 2023 | 8:17 pm

COTY

DA Davidson analyst Linda Bolton Weiser reiterated a Buy rating on Coty Inc (NYSE:COTY) and raised the price target from $15 to $17. Coty reported Q1 FY24 sales growth of 18% YoY to $1.64 billion, beating the consensus estimate of $1.58 billion. E-commerce sales were up more than 25% YoY. Coty issued 33 million shares to facilitate ownership by European investors and build liquidity in Europe. The company expects to repurchase 27 million shares in Q3. FY24 is expected to be the third consecutive year of double-digit organic sales growth and EBITDA growth of 8% or higher.

Portfolio Pulse from Shivani Kumaresan

November 08, 2023 | 8:16 pm

XNCR

RBC Capital analyst Gregory Renza has maintained an 'Outperform' rating on Xencor (NASDAQ:XNCR), but lowered the price target from $36 to $32.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 8:15 pm

BTAI

MRK

BioXcel Therapeutics announced overall survival data from its Phase 2 trial of BXCL701 in combination with Merck's Keytruda in patients with metastatic castration-resistant prostate cancer. The company reported a RECIST partial response rate of 28% with a median duration of response of 19 months. BioXcel is also evaluating strategic options for its subsidiary OnkosXcel Therapeutics, including potential financing, strategic partnership, or M&A. BTAI shares are down 6.78% at $4.51.

Portfolio Pulse from Vandana Singh

November 08, 2023 | 8:15 pm

CTOS

JP Morgan analyst Tami Zakaria maintains a Neutral rating on Custom Truck One Source (NYSE:CTOS) and lowers the price target from $7.5 to $7.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 8:13 pm

UPWK

RBC Capital analyst Brad Erickson has maintained a 'Sector Perform' rating on Upwork (NASDAQ:UPWK) and raised the price target from $11 to $17.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 8:13 pm

CNHI

JP Morgan analyst Ann Duignan maintains a Neutral rating on CNH Industrial (NYSE:CNHI) and lowers the price target from $14 to $12.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 8:11 pm

SAGE

RBC Capital analyst Brian Abrahams has maintained a 'Sector Perform' rating on Sage Therapeutics (NASDAQ:SAGE) and lowered the price target from $22 to $21.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 8:11 pm